EzCatDB: D00864

DB codeD00864
RLCP classification1.30.35885.972
CATH domainDomain 13.20.20.80Catalytic domain
Domain 22.60.40.1180
E.C.3.2.1.45
CSA2f61

CATH domainRelated DB codes (homologues)
2.60.40.1180M00113,T00307,D00165,D00176,D00664,D00665,D00863,M00112,M00193,M00314,T00057,T00062,T00067
3.20.20.80S00202,S00210,S00748,S00906,S00907,S00911,S00912,S00915,M00134,M00160,D00479,S00204,S00205,S00206,S00207,S00203,S00208,S00209,S00211,S00213,S00214,M00113,T00307,D00165,D00166,D00169,D00176,D00501,D00502,D00503,D00844,D00861,M00026,M00112,M00193,M00346,T00057,T00062,T00063,T00066,T00067

Enzyme Name
Swiss-protKEGG

Q9BDT0P04062
Protein nameGlucosylceramidaseGlucosylceramidaseGlucosylceramidase
Psychosine hydrolase
Glucosphingosine glucosylhydrolase
GlcCer-beta-glucosidase
beta-D-Glucocerebrosidase
Glucosylcerebrosidase
beta-Glucosylceramidase
Ceramide glucosidase
Glucocerebrosidase
Glucosylsphingosine beta-glucosidase
Glucosylsphingosine beta-D-glucosidase
SynonymsEC 3.2.1.45
Beta-glucocerebrosidase
Acid beta-glucosidase
D-glucosyl-N-acylsphingosine glucohydrolase
EC 3.2.1.45
Beta-glucocerebrosidase
Acid beta-glucosidase
D-glucosyl-N-acylsphingosine glucohydrolase
Alglucerase
Imiglucerase

KEGG pathways
MAP codePathways
MAP00600Sphingolipid metabolism
MAP01032Glycan structures - degradation

Swiss-prot:Accession NumberQ9BDT0P04062
Entry nameGLCM_PANTRGLCM_HUMAN
ActivityD-glucosyl-N-acylsphingosine + H(2)O = D-glucose + N-acylsphingosine.D-glucosyl-N-acylsphingosine + H(2)O = D-glucose + N-acylsphingosine.
SubunitInteracts with SCARB2 (By similarity).Interacts with saposin-C.
Subcellular locationLysosome membrane, Peripheral membrane protein (By similarity). Note=Targeting to lysosomes occurs through an alternative MPR-independent mechanism via SCARB2 (By similarity).Lysosome membrane, Peripheral membrane protein, Lumenal side. Note=Interaction with saposin-C promotes membrane association.
Cofactor



SubstratesProductsintermediates
KEGG-idC01190C00001C00031C00195I00122
CompoundD-glucosyl-N-acylsphingosineH2OD-glucoseN-acylsphingosinePeptidyl-Glu-Glucose
Typeamide group,carbohydrate,lipidH2Ocarbohydrateamide group,carbohydrate,lipid
2vt0A01Unbound
UnboundUnboundIntermediate-analogue:CBU
2vt0B01Unbound
UnboundUnboundIntermediate-analogue:CBU
1ogsA01Unbound
UnboundUnboundUnbound
1ogsB01Unbound
UnboundUnboundUnbound
1y7vA01Unbound
UnboundUnboundIntermediate-analogue:INS
1y7vB01Unbound
UnboundUnboundIntermediate-analogue:INS
2f61A01Unbound
UnboundUnboundUnbound
2f61B01Unbound
UnboundUnboundUnbound
2j25A01Unbound
UnboundUnboundUnbound
2j25B01Unbound
UnboundUnboundUnbound
2nsxA01Unbound
UnboundUnboundUnbound
2nsxB01Unbound
Analogue:IFMUnboundUnbound
2nsxC01Unbound
UnboundUnboundUnbound
2nsxD01Unbound
Analogue:IFMUnboundUnbound
2nt0A01Unbound
UnboundUnboundUnbound
2nt0B01Unbound
UnboundUnboundUnbound
2nt0C01Unbound
UnboundUnboundUnbound
2nt0D01Unbound
UnboundUnboundUnbound
2nt1A01Unbound
UnboundUnboundUnbound
2nt1B01Unbound
UnboundUnboundUnbound
2nt1C01Unbound
UnboundUnboundUnbound
2nt1D01Unbound
UnboundUnboundUnbound
2v3dA01Analogue:NBV
UnboundUnboundUnbound
2v3dB01Analogue:NBV
UnboundUnboundUnbound
2v3eA01Analogue:NND
UnboundUnboundUnbound
2v3eB01Analogue:NND
UnboundUnboundUnbound
2v3fA01Unbound
UnboundUnboundUnbound
2v3fB01Unbound
UnboundUnboundUnbound
2wcgA01Unbound
Analogue:MT5UnboundUnbound
2wcgB01Unbound
Analogue:MT5UnboundUnbound
2wklA01Unbound
UnboundUnboundUnbound
2wklB01Unbound
UnboundUnboundUnbound
2xwdA01Unbound
Analogue:LGSUnboundUnbound
2xwdB01Unbound
Analogue:LGSUnboundUnbound
2xweA01Analogue:AMF
UnboundUnboundUnbound
2xweB01Analogue:AMF
UnboundUnboundUnbound
3gxdA01Unbound
UnboundUnboundUnbound
3gxdB01Unbound
UnboundUnboundUnbound
3gxdC01Unbound
UnboundUnboundUnbound
3gxdD01Unbound
UnboundUnboundUnbound
3gxfA01Unbound
UnboundUnboundUnbound
3gxfB01Unbound
Analogue:IFMUnboundUnbound
3gxfC01Unbound
UnboundUnboundUnbound
3gxfD01Unbound
Analogue:IFMUnboundUnbound
3gxiA01Unbound
UnboundUnboundUnbound
3gxiB01Unbound
UnboundUnboundUnbound
3gxiC01Unbound
UnboundUnboundUnbound
3gxiD01Unbound
UnboundUnboundUnbound
3gxmA01Unbound
UnboundUnboundUnbound
3gxmB01Unbound
UnboundUnboundUnbound
3gxmC01Unbound
UnboundUnboundUnbound
3gxmD01Unbound
UnboundUnboundUnbound
3ke0A01Unbound
UnboundUnboundUnbound
3ke0B01Unbound
UnboundUnboundUnbound
3kehA01Unbound
UnboundUnboundUnbound
3kehB01Unbound
UnboundUnboundUnbound
2vt0A02Unbound
UnboundUnboundUnbound
2vt0B02Unbound
UnboundUnboundUnbound
1ogsA02Unbound
UnboundUnboundUnbound
1ogsB02Unbound
UnboundUnboundUnbound
1y7vA02Unbound
UnboundUnboundUnbound
1y7vB02Unbound
UnboundUnboundUnbound
2f61A02Unbound
UnboundUnboundUnbound
2f61B02Unbound
UnboundUnboundUnbound
2j25A02Unbound
UnboundUnboundUnbound
2j25B02Unbound
UnboundUnboundUnbound
2nsxA02Unbound
UnboundUnboundUnbound
2nsxB02Unbound
UnboundUnboundUnbound
2nsxC02Unbound
UnboundUnboundUnbound
2nsxD02Unbound
UnboundUnboundUnbound
2nt0A02Unbound
UnboundUnboundUnbound
2nt0B02Unbound
UnboundUnboundUnbound
2nt0C02Unbound
UnboundUnboundUnbound
2nt0D02Unbound
UnboundUnboundUnbound
2nt1A02Unbound
UnboundUnboundUnbound
2nt1B02Unbound
UnboundUnboundUnbound
2nt1C02Unbound
UnboundUnboundUnbound
2nt1D02Unbound
UnboundUnboundUnbound
2v3dA02Unbound
UnboundUnboundUnbound
2v3dB02Unbound
UnboundUnboundUnbound
2v3eA02Unbound
UnboundUnboundUnbound
2v3eB02Unbound
UnboundUnboundUnbound
2v3fA02Unbound
UnboundUnboundUnbound
2v3fB02Unbound
UnboundUnboundUnbound
2wcgA02Unbound
UnboundUnboundUnbound
2wcgB02Unbound
UnboundUnboundUnbound
2wklA02Unbound
UnboundUnboundUnbound
2wklB02Unbound
UnboundUnboundUnbound
2xwdA02Unbound
UnboundUnboundUnbound
2xwdB02Unbound
UnboundUnboundUnbound
2xweA02Unbound
UnboundUnboundUnbound
2xweB02Unbound
UnboundUnboundUnbound
3gxdA02Unbound
UnboundUnboundUnbound
3gxdB02Unbound
UnboundUnboundUnbound
3gxdC02Unbound
UnboundUnboundUnbound
3gxdD02Unbound
UnboundUnboundUnbound
3gxfA02Unbound
UnboundUnboundUnbound
3gxfB02Unbound
UnboundUnboundUnbound
3gxfC02Unbound
UnboundUnboundUnbound
3gxfD02Unbound
UnboundUnboundUnbound
3gxiA02Unbound
UnboundUnboundUnbound
3gxiB02Unbound
UnboundUnboundUnbound
3gxiC02Unbound
UnboundUnboundUnbound
3gxiD02Unbound
UnboundUnboundUnbound
3gxmA02Unbound
UnboundUnboundUnbound
3gxmB02Unbound
UnboundUnboundUnbound
3gxmC02Unbound
UnboundUnboundUnbound
3gxmD02Unbound
UnboundUnboundUnbound
3ke0A02Unbound
UnboundUnboundUnbound
3ke0B02Unbound
UnboundUnboundUnbound
3kehA02Unbound
UnboundUnboundUnbound
3kehB02Unbound
UnboundUnboundUnbound

Active-site residues
resource
literature [5], [7]
pdbCatalytic residuescomment
2vt0A01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2vt0B01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

1ogsA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

1ogsB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

1y7vA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

1y7vB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2f61A01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2f61B01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2j25A01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2j25B01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2nsxA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2nsxB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2nsxC01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2nsxD01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2nt0A01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2nt0B01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2nt0C01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2nt0D01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2nt1A01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2nt1B01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2nt1C01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2nt1D01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2v3dA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2v3dB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2v3eA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2v3eB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2v3fA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2v3fB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2wcgA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2wcgB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2wklA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2wklB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2xwdA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2xwdB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2xweA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

2xweB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxdA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxdB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxdC01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxdD01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxfA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxfB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxfC01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxfD01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxiA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxiB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxiC01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxiD01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxmA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxmB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxmC01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3gxmD01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340

3ke0A01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340
mutant N370S
3ke0B01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340
mutant N370S
3kehA01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340
mutant N370S
3kehB01ARG 120;ASN 234;GLU 235;HIS 311;TYR 313;GLU 340
mutant N370S
2vt0A02

2vt0B02

1ogsA02

1ogsB02

1y7vA02

1y7vB02

2f61A02

2f61B02

2j25A02

2j25B02

2nsxA02

2nsxB02

2nsxC02

2nsxD02

2nt0A02

2nt0B02

2nt0C02

2nt0D02

2nt1A02

2nt1B02

2nt1C02

2nt1D02

2v3dA02

2v3dB02

2v3eA02

2v3eB02

2v3fA02

2v3fB02

2wcgA02

2wcgB02

2wklA02

2wklB02

2xwdA02

2xwdB02

2xweA02

2xweB02

3gxdA02

3gxdB02

3gxdC02

3gxdD02

3gxfA02

3gxfB02

3gxfC02

3gxfD02

3gxiA02

3gxiB02

3gxiC02

3gxiD02

3gxmA02

3gxmB02

3gxmC02

3gxmD02

3ke0A02

3ke0B02

3kehA02

3kehB02


References for Catalytic Mechanism
ReferencesSectionsNo. of steps in catalysis
[3]Fig.1, p.886, p.890
[6]Fig.1, p.853
[12]p.4242
[14]Fig.6, p.29055-29057

references
[1]
PubMed ID3927728
JournalAm J Med Genet
Year1985
Volume21
Pages529-49
AuthorsGrabowski GA, Goldblatt J, Dinur T, Kruse J, Svennerholm L, Gatt S, Desnick RJ
TitleGenetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients.
[2]
PubMed ID1714449
JournalJ Biol Chem
Year1991
Volume266
Pages15021-7
AuthorsFabbro D, Grabowski GA
TitleHuman acid beta-glucosidase. Use of inhibitory and activating monoclonal antibodies to investigate the enzyme's catalytic mechanism and saposin A and C binding sites.
[3]
PubMed ID7712292
JournalCurr Opin Struct Biol
Year1994
Volume4
Pages885-92
AuthorsMcCarter JD, Withers SG
TitleMechanisms of enzymatic glycoside hydrolysis.
[4]
PubMed ID8294487
JournalJ Biol Chem
Year1994
Volume269
Pages2283-91
AuthorsGrace ME, Newman KM, Scheinker V, Berg-Fussman A, Grabowski GA
TitleAnalysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression.
[5]
PubMed ID7908905
JournalJ Biol Chem
Year1994
Volume269
Pages10975-8
AuthorsMiao S, McCarter JD, Grace ME, Grabowski GA, Aebersold R, Withers SG
TitleIdentification of Glu340 as the active-site nucleophile in human glucocerebrosidase by use of electrospray tandem mass spectrometry.
Related Swiss-protP04062
[6]
PubMed ID8535779
JournalStructure
Year1995
Volume3
Pages853-9
AuthorsDavies G, Henrissat B
TitleStructures and mechanisms of glycosyl hydrolases.
[7]
PubMed ID11087714
JournalGlycobiology
Year2000
Volume10
Pages1217-24
AuthorsFabrega S, Durand P, Codogno P, Bauvy C, Delomenie C, Henrissat B, Martin BM, McKinney C, Ginns EI, Mornon JP, Lehn P
TitleHuman glucocerebrosidase: heterologous expression of active site mutants in murine null cells.
[8]
CommentsX-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 40-536, GLYCOSYLATION AT ASN-58, AND DISULFIDE BONDS.
PubMed ID12792654
JournalEMBO Rep
Year2003
Volume4
Pages704-9
AuthorsDvir H, Harel M, McCarthy AA, Toker L, Silman I, Futerman AH, Sussman JL
TitleX-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease.
Related PDB1ogs
Related Swiss-protP04062
[9]
PubMed ID15019270
JournalTrends Pharmacol Sci
Year2004
Volume25
Pages147-51
AuthorsFuterman AH, Sussman JL, Horowitz M, Silman I, Zimran A
TitleNew directions in the treatment of Gaucher disease.
[10]
CommentsX-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 40-536 IN COMPLEX WITH SYNTHETIC INHIBITOR, ACTIVE SITE.
PubMed ID15817452
JournalJ Biol Chem
Year2005
Volume280
Pages23815-9
AuthorsPremkumar L, Sawkar AR, Boldin-Adamsky S, Toker L, Silman I, Kelly JW, Futerman AH, Sussman JL
TitleX-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease.
Related PDB1y7v
Related Swiss-protP04062
[11]
CommentsX-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 40-536, AND GLYCOSYLATION AT ASN-58; ASN-98 AND ASN-185.
PubMed ID17139081
JournalActa Crystallogr D Biol Crystallogr
Year2006
Volume62
Pages1458-65
AuthorsBrumshtein B, Wormald MR, Silman I, Futerman AH, Sussman JL
TitleStructural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease.
Related PDB2j25
Related Swiss-protP04062
[12]
CommentsX-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 40-536, CHARACTERIZATION OF GD VARIANTS SER-55; GLN-87; ASN-118; GLN-159; LEU-161; VAL-162; VAL-166; ASN-200; PHE-213; PHE-224; GLU-232; GLU-237; LEU-298; ILE-303; CYS-343; ILE-362; LYS-365; GLY-381; LYS-388; TRP-392; CYS-402; SER-409; VAL-410; HIS-419; LYS-421; ARG-429; LEU-433; SER-436; ASN-438; HIS-448; VAL-455; PRO-483; PRO-500 AND PRO-502, AND MUTAGENESIS OF CYS-43; CYS-57 AND CYS-62.
PubMed ID16293621
JournalJ Biol Chem
Year2006
Volume281
Pages4242-53
AuthorsLiou B, Kazimierczuk A, Zhang M, Scott CR, Hegde RS, Grabowski GA
TitleAnalyses of variant acid beta-glucosidases: effects of Gaucher disease mutations.
Related PDB2f61
Related Swiss-protP04062
[13]
PubMed ID17894779
JournalFEBS J
Year2007
Volume274
Pages4944-50
AuthorsYu Z, Sawkar AR, Kelly JW
TitlePharmacologic chaperoning as a strategy to treat Gaucher disease.
[14]
CommentsX-RAY CRYSTALLOGRAPHY
PubMed ID17666401
JournalJ Biol Chem
Year2007
Volume282
Pages29052-8
AuthorsBrumshtein B, Greenblatt HM, Butters TD, Shaaltiel Y, Aviezer D, Silman I, Futerman AH, Sussman JL
TitleCrystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease.
Related PDB2v3e,2v3d
[15]
PubMed ID17713797
JournalJ Mol Model
Year2007
Volume13
Pages1133-9
AuthorsZubrzycki IZ, Borcz A, Wiacek M, Hagner W
TitleThe studies on substrate, product and inhibitor binding to a wild-type and neuronopathic form of human acid-beta-glucosidase.
[16]
CommentsX-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 40-536 IN COMPLEXES WITH ISOFAGOMINE, AND SUBCELLULAR LOCATION.
PubMed ID17187079
JournalNat Chem Biol
Year2007
Volume3
Pages101-7
AuthorsLieberman RL, Wustman BA, Huertas P, Powe AC Jr, Pine CW, Khanna R, Schlossmacher MG, Ringe D, Petsko GA
TitleStructure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
Related PDB2nt0,2nt1,2nsx
Related Swiss-protP04062
[17]
CommentsX-RAY CRYSTALLOGRAPHY
PubMed ID17524049
JournalPlant Biotechnol J
Year2007
Volume5
Pages579-90
AuthorsShaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D
TitleProduction of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.
Related PDB2v3f
[18]
PubMed ID18783340
JournalBiol Chem
Year2008
Volume389
Pages1361-9
AuthorsKacher Y, Brumshtein B, Boldin-Adamsky S, Toker L, Shainskaya A, Silman I, Sussman JL, Futerman AH
TitleAcid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy.
Related PDB2vt0
[19]
PubMed ID19374450
JournalBiochemistry
Year2009
Volume48
Pages4816-27
AuthorsLieberman RL, D'aquino JA, Ringe D, Petsko GA
TitleEffects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.
Related PDB3gxd,3gxf,3gxi,3gxm
[20]
PubMed ID19437524
JournalChembiochem
Year2009
Volume10
Pages1480-5
AuthorsBrumshtein B, Aguilar-Moncayo M, Garc?a-Moreno MI, Ortiz Mellet C, Garc?a Fern?ndez JM, Silman I, Shaaltiel Y, Aviezer D, Sussman JL, Futerman AH
Title6-Amino-6-deoxy-5,6-di-N-(N'-octyliminomethylidene)nojirimycin: synthesis, biological evaluation, and crystal structure in complex with acid beta-glucosidase.
Related PDB2wcg
[21]
PubMed ID20980263
JournalJ Biol Chem
Year2011
Volume286
Pages299-308
AuthorsWei RR, Hughes H, Boucher S, Bird JJ, Guziewicz N, Van Patten SM, Qiu H, Pan CQ, Edmunds T
TitleX-ray and biochemical analysis of N370S mutant human acid ??-glucosidase.
Related PDB3ke0,3keh
[22]
PubMed ID21483943
JournalOrg Biomol Chem
Year2011
Volume9
Pages4160-7
AuthorsBrumshtein B, Aguilar-Moncayo M, Benito JM, Garc?a Fernandez JM, Silman I, Shaaltiel Y, Aviezer D, Sussman JL, Futerman AH, Ortiz Mellet C
TitleCyclodextrin-mediated crystallization of acid ??-glucosidase in complex with amphiphilic bicyclic nojirimycin analogues.
Related PDB2xwd,2xwe

comments
This enzyme belongs to glycosidase family-30, with a retaining mechanism.
This enzyme seems to be distantly related to beta-xylosidase (EC 3.2.1.37; D00844 in EzCatDB) from glycosidase family-39, and the catalytic residues of the counterpart enzyme can be superimposed with the corresponding residues. According to the literature [14], [16] and [18], these residues are located at the active site, along with the nucleophilic residue, Glu340, and general acid-base, Glu235.
The reaction may proceeds as follows:
(0) Arg120 and Tyr313 may modulate the activity of catalytic nucleophile, Glu340, whereas His311 may modulate the activity of a general acid-base, Glu235.
(1) Glu235 acts as a general acid to protonate the leaving oxygen, O4 atom at subsite +1, forming an oxocarbenium-ion-like transition-state. The transition-state is stabilized by Asn234 and Tyr313 through hydrogen bonding to the oxygen atoms of glucosyl group. (SN1-like reaction)
(2) Glu340 makes a nucleophilic attack on C1 atom of substrate, glucose, to form a covalent intermediate with the glucose unit.
(3) Glu235 acts as a general base to deprotonate a water molecule, to activate it.
(4) The activated water makes a nucleophilic attack on the C1 atom of the covalent intermediate. Thus, the substitution reaction completes.

createdupdated
2008-05-132012-02-14


Copyright: Nozomi Nagano, JST & CBRC-AIST
Funded by PRESTO/Japan Science and Technology Corporation (JST) (December 2001 - November 2004)
Funded by Grant-in-Aid for Publication of Scientific Research Results/Japan Society for the Promotion of Science (JSPS) (April 2005 - March 2006)
Funded by Grant-in-Aid for Scientific Research (B)/Japan Society for the Promotion of Science (JSPS) (April 2005 - March 2008)
Funded by BIRD/Japan Science and Technology Corporation (JST) (September 2005 - September 2010)
Funded by BIRD/Japan Science and Technology Corporation (JST) (October 2007 - September 2010)
Funded by Grant-in-Aid for Publication of Scientific Research Results/Japan Society for the Promotion of Science (JSPS) (April 2011 - March 2012)

© Computational Biology Research Center, AIST, 2004 All Rights Reserved.